RxDoctor Payments DataLook up a doctor →

James Butrynski, MD

Hematology & Oncology · Eugene, ORNPI 1427134287

Payments from drug & device makers

$732,306in general payments, 2019–2025

Across 416 payments — averaging $1760.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mirati Therapeutics, Inc.$421K
  • AstraZeneca$102K
  • Genentech, Inc.$82K
  • Janssen Research & Development, LLC$30K
  • Eli Lilly$28K
  • Amgen$15K
  • plus $55K from 10 others
$21,400in research payments, 2019–2025

Across 38 payments — averaging $563.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Scientific Affairs, LLC$21K

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$732,306 in reported general payments places this provider in the 80th percentile of 112 hematology & oncology providers in Oregon.

See all hematology & oncology providers in Oregon

Medicare billing

Part B allowed, 2024
$1,512,541
Medicare patients
469
Services billed
66,001

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Eugene

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →